Completed PHASE2 INTERVENTIONAL 2-arm NCT00509067

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia (STAR-1)

Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia

Sponsor: Georgetown University

Interventions CDP-choline Galantamine Placebo risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole

Updated 7 times since 2017 Last updated: Mar 13, 2018 Started: Nov 30, 2007 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Schizophrenia and is currently completed. Georgetown University leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Georgetown University
National Institute of Mental Health (NIMH)
Washington D.C. Veterans Affairs Medical Center

Data source: Georgetown University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Washington D.C., United States